BEAM
Price
$16.80
Change
-$0.34 (-1.98%)
Updated
Jun 27 closing price
Capitalization
1.69B
44 days until earnings call
NAMS
Price
$18.57
Change
+$0.12 (+0.65%)
Updated
Jun 27 closing price
Capitalization
2.08B
44 days until earnings call
Interact to see
Advertisement

BEAM vs NAMS

Header iconBEAM vs NAMS Comparison
Open Charts BEAM vs NAMSBanner chart's image
Beam Therapeutics
Price$16.80
Change-$0.34 (-1.98%)
Volume$4.49M
Capitalization1.69B
NewAmsterdam Pharma
Price$18.57
Change+$0.12 (+0.65%)
Volume$1.24M
Capitalization2.08B
BEAM vs NAMS Comparison Chart in %
Loading...
BEAM
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
NAMS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
BEAM vs. NAMS commentary
Jun 29, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BEAM is a Buy and NAMS is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 29, 2025
Stock price -- (BEAM: $16.80 vs. NAMS: $18.57)
Brand notoriety: BEAM and NAMS are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: BEAM: 238% vs. NAMS: 153%
Market capitalization -- BEAM: $1.69B vs. NAMS: $2.08B
BEAM [@Biotechnology] is valued at $1.69B. NAMS’s [@Biotechnology] market capitalization is $2.08B. The market cap for tickers in the [@Biotechnology] industry ranges from $299.85B to $0. The average market capitalization across the [@Biotechnology] industry is $2.3B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

BEAM’s FA Score shows that 1 FA rating(s) are green whileNAMS’s FA Score has 1 green FA rating(s).

  • BEAM’s FA Score: 1 green, 4 red.
  • NAMS’s FA Score: 1 green, 4 red.
According to our system of comparison, NAMS is a better buy in the long-term than BEAM.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

BEAM’s TA Score shows that 3 TA indicator(s) are bullish while NAMS’s TA Score has 2 bullish TA indicator(s).

  • BEAM’s TA Score: 3 bullish, 5 bearish.
  • NAMS’s TA Score: 2 bullish, 8 bearish.
According to our system of comparison, BEAM is a better buy in the short-term than NAMS.

Price Growth

BEAM (@Biotechnology) experienced а +0.18% price change this week, while NAMS (@Biotechnology) price change was +3.40% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +4.13%. For the same industry, the average monthly price growth was +31.22%, and the average quarterly price growth was +12.91%.

Reported Earning Dates

BEAM is expected to report earnings on Aug 12, 2025.

NAMS is expected to report earnings on Aug 12, 2025.

Industries' Descriptions

@Biotechnology (+4.13% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
NAMS($2.09B) has a higher market cap than BEAM($1.69B). NAMS YTD gains are higher at: -27.743 vs. BEAM (-32.258). NAMS has higher annual earnings (EBITDA): -254.89M vs. BEAM (-399.03M). BEAM has more cash in the bank: 1.22B vs. NAMS (808M). NAMS has less debt than BEAM: NAMS (389K) vs BEAM (158M). BEAM has higher revenues than NAMS: BEAM (63.6M) vs NAMS (47.1M).
BEAMNAMSBEAM / NAMS
Capitalization1.69B2.09B81%
EBITDA-399.03M-254.89M157%
Gain YTD-32.258-27.743116%
P/E RatioN/AN/A-
Revenue63.6M47.1M135%
Total Cash1.22B808M151%
Total Debt158M389K40,617%
TECHNICAL ANALYSIS
Technical Analysis
BEAMNAMS
RSI
ODDS (%)
N/A
Bearish Trend 3 days ago
63%
Stochastic
ODDS (%)
Bullish Trend 3 days ago
84%
Bullish Trend 3 days ago
59%
Momentum
ODDS (%)
Bearish Trend 3 days ago
90%
Bearish Trend 3 days ago
45%
MACD
ODDS (%)
Bullish Trend 3 days ago
89%
Bearish Trend 3 days ago
45%
TrendWeek
ODDS (%)
Bullish Trend 3 days ago
81%
Bullish Trend 3 days ago
53%
TrendMonth
ODDS (%)
Bearish Trend 3 days ago
84%
Bullish Trend 3 days ago
54%
Advances
ODDS (%)
Bullish Trend 12 days ago
78%
Bullish Trend 3 days ago
73%
Declines
ODDS (%)
Bearish Trend 14 days ago
85%
Bearish Trend 10 days ago
71%
BollingerBands
ODDS (%)
Bearish Trend 3 days ago
84%
Bearish Trend 3 days ago
55%
Aroon
ODDS (%)
Bearish Trend 3 days ago
85%
Bearish Trend 3 days ago
67%
View a ticker or compare two or three
Interact to see
Advertisement
BEAM
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
NAMS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
RYANX137.441.03
+0.76%
Rydex Nova A
VKSRX20.370.07
+0.34%
Virtus KAR Small-Mid Cap Core R6
PVFAX52.440.12
+0.23%
Paradigm Value
GSATX31.690.01
+0.03%
Goldman Sachs Small Cp Val Insghts A
HBLFX14.63N/A
N/A
Hartford Balanced Income F

BEAM and

Correlation & Price change

A.I.dvisor indicates that over the last year, BEAM has been closely correlated with CRSP. These tickers have moved in lockstep 72% of the time. This A.I.-generated data suggests there is a high statistical probability that if BEAM jumps, then CRSP could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To BEAM
1D Price
Change %
BEAM100%
-1.98%
CRSP - BEAM
72%
Closely correlated
N/A
RXRX - BEAM
64%
Loosely correlated
-6.85%
NTLA - BEAM
63%
Loosely correlated
-0.52%
DNLI - BEAM
61%
Loosely correlated
-2.69%
SYRE - BEAM
59%
Loosely correlated
-4.99%
More

NAMS and

Correlation & Price change

A.I.dvisor indicates that over the last year, NAMS has been loosely correlated with QURE. These tickers have moved in lockstep 50% of the time. This A.I.-generated data suggests there is some statistical probability that if NAMS jumps, then QURE could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To NAMS
1D Price
Change %
NAMS100%
+0.65%
QURE - NAMS
50%
Loosely correlated
-2.46%
CRDF - NAMS
41%
Loosely correlated
-0.32%
IRON - NAMS
37%
Loosely correlated
+0.68%
BEAM - NAMS
35%
Loosely correlated
-1.98%
AUPH - NAMS
35%
Loosely correlated
+0.12%
More